Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients
Por:
Estrada, N, Zamora, L, Ferrer-Marin, F, Palomo, L, Garcia, O, Velez, P, De la Fuente, I, Sagues, M, Cabezon, M, Cortes, M, Vallansot, RO, Senin-Magan, MA, Boque, C and Xicoy, B
Publicada:
1 oct 2022
Resumen:
Imatinib is the most common first-line tyrosine kinase inhibitor (TKI) used to treat chronic-phase chronic myeloid leukemia (CP-CML). However, only a proportion of patients achieve major molecular response (MMR), so there is a need to find biological factors that aid the selection of the optimal therapeutic strategy (imatinib vs. more potent second-generation TKIs). The aim of this retrospective study was to understand the contribution of germline single-nucleotide variants (gSNVs) in the achievement of MMR with imatinib. In particular, a discovery cohort including 45 CP-CML patients was analyzed through the DMET array, which interrogates 1936 variants in 231 genes related to the absorption, distribution, metabolism and excretion (ADME) process. Variants statistically significant in the discovery cohort were then tested in an extended and independent cohort of 137 CP-CML patients. Finally, a total of 7 gSNVs (ABCG1-rs492338, ABCB11-rs496550, ABCB11-rs497692, CYP2D6-rs1135840, CYP11B1-rs7003319, MAT1A-rs4934027 and SLC22A1-rs628031) and one haplotype in the ABCB11 gene were significantly associated with the achievement of MMR with first-line imatinibtreatment. In conclusion, we identified a genetic signature of response to imatinib in CP-CML patients that could be useful in selecting those patients that may benefit from starting imatinib as first-line therapy, therefore avoiding the toxicity related to second-generation TKIs.
Filiaciones:
:
Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst, Myeloid Neoplasms Grp, Badalona 08916, Spain
:
Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst, Myeloid Neoplasms Grp, Badalona 08916, Spain
Ferrer-Marin, F:
Hosp Gen Univ Morales Meseguer, UCAM, IMIB Pascual Parrilla, CIBERER CB15 00055, Murcia 30008, Spain
:
Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst, MDS Grp, Badalona 08916, Spain
Vall dHebron Inst Oncol VHIO, Expt Hematol, Barcelona 08035, Spain
Garcia, O:
Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst, Myeloid Neoplasms Grp, Badalona 08916, Spain
Velez, P:
ICO Hosp Duran & Reynals, Barcelona 08908, Spain
De la Fuente, I:
ICO Hosp Josep Trueta, Girona 17007, Spain
Sagues, M:
ICO Hosp Josep Trueta, Girona 17007, Spain
:
Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst, Myeloid Neoplasms Grp, Badalona 08916, Spain
Cortes, M:
Hosp Granollers, Granollers 08402, Spain
Vallansot, RO:
Hosp Joan 23, ICO Tarragona, Tarragona 43005, Spain
Senin-Magan, MA:
ICO Hosp Duran & Reynals, Barcelona 08908, Spain
Boque, C:
ICO Hosp Duran & Reynals, Barcelona 08908, Spain
:
Univ Autonoma Barcelona, ICO Hosp Germans Trias & Pujol, Josep Carreras Leukaemia Res Inst, Myeloid Neoplasms Grp, Badalona 08916, Spain
Green Published, gold
|